Trium Capital LLP Purchases New Shares in Quanterix Corporation (NASDAQ:QTRX)

Trium Capital LLP purchased a new stake in Quanterix Corporation (NASDAQ:QTRX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 559,500 shares of the company's stock, valued at approximately $3,642,000. Quanterix makes up 0.5% of Trium Capital LLP's holdings, making the stock its 14th largest holding. Trium Capital LLP owned 1.44% of Quanterix at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of QTRX. JPMorgan Chase & Co. raised its position in shares of Quanterix by 23.9% in the 4th quarter. JPMorgan Chase & Co. now owns 270,054 shares of the company's stock valued at $2,871,000 after purchasing an additional 52,097 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Quanterix in the 4th quarter valued at approximately $606,000. Price T Rowe Associates Inc. MD raised its position in shares of Quanterix by 18.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company's stock valued at $361,000 after purchasing an additional 5,385 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Quanterix in the 4th quarter valued at approximately $570,000. Finally, Jane Street Group LLC raised its position in shares of Quanterix by 18.1% in the 4th quarter. Jane Street Group LLC now owns 55,947 shares of the company's stock valued at $595,000 after purchasing an additional 8,578 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 price objective (down from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. Canaccord Genuity Group reduced their price target on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $13.50.

Insider Buying and Selling

In other news, Director David R. Walt acquired 123,990 shares of the company's stock in a transaction dated Friday, June 13th. The shares were acquired at an average price of $6.14 per share, with a total value of $761,298.60. Following the purchase, the director directly owned 1,866,933 shares of the company's stock, valued at $11,462,968.62. This trade represents a 7.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William P. Donnelly acquired 93,113 shares of the company's stock in a transaction dated Friday, June 6th. The shares were purchased at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the purchase, the director directly owned 139,094 shares in the company, valued at approximately $756,671.36. This trade represents a 202.50% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 463,113 shares of company stock worth $2,625,444 in the last ninety days. Corporate insiders own 6.90% of the company's stock.

Quanterix Price Performance

QTRX traded up $0.03 during trading on Friday, reaching $5.89. 518,730 shares of the company's stock were exchanged, compared to its average volume of 613,067. Quanterix Corporation has a 1 year low of $4.05 and a 1 year high of $16.74. The stock has a market capitalization of $294.21 million, a P/E ratio of -4.53 and a beta of 1.13. The company's fifty day simple moving average is $5.72 and its 200-day simple moving average is $7.04.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.16. The company had revenue of $30.33 million during the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative net margin of 36.82% and a negative return on equity of 15.07%. Equities analysts forecast that Quanterix Corporation will post -0.98 EPS for the current year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.